Article
Gastroenterology & Hepatology
Haggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, Sigal Pressman, Amjad Mousa, Edmond Sabo, Matti Waterman, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers
Summary: Therapeutic drug monitoring is essential when guiding anti-TNF therapy for inflammatory bowel disease. This study found differences in tissue dynamics between infliximab and adalimumab, with SDL correlating with tissue free drug levels. Understanding these interactions could lead to improved therapeutic strategies in the future.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Rheumatology
Alba Herrero-Morant, Jose Luis Martin-Varillas, Santos Castaneda, Olga Maiz, Julio Sanchez, Norberto Ortego, Enrique Raya, Agueda Prior-Espanol, Clara Moriano, Rafael B. Melero-Gonzalez, Jenaro Grana-Gil, Ana Urruticoechea-Arana, Angel Ramos-Calvo, Marta Loredo-Martinez, Eva Salgado-Perez, Francisca Sivera, Ignacio Torre, Javier Narvaez, Jose Luis Andreu, Olga Martinez-Gonzalez, Ricardo Gomez-de la Torre, Sabela Fernandez-Aguado, Susana Romero-Yuste, Inigo Gonzalez-Mazon, Carmen Alvarez-Reguera, Jose Luis Hernandez, Miguel angel Gonzalez-Gay, Ricardo Blanco
Summary: Biologic therapy appears to be effective and relatively safe in refractory neurobehcet's disease.
Article
Gastroenterology & Hepatology
Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy
Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Anne Emmanuelle Berger, Aude Gleizes, Louis Waeckel, Xavier Roblin, Roman Krzysiek, Salima Hacein-Bey-Abina, Alessandra Soriano, Stephane Paul
Summary: This study evaluated the application performance of a new chemiluminescent instrument (i-TRACK10(R)) in clinical decision-making. The results showed satisfactory intra- and inter-run performances of i-TRACK10(R) and generally comparable results to manual or automated ELISA. However, due to differences in anti-drug antibodies, it is recommended to use the same assay in the long-term follow-up of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Alexa N. Sasson, Ashwin N. Ananthakrishnan
Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Dermatology
N. Onsun, B. Gunes, G. Kaya, Guckan B. Isik, Yabaci A. Tak
Summary: This study evaluates the long-term survival rates of adalimumab and infliximab based on real-life clinical data, and finds that the efficacy of these two drugs decreases over time.
Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Guillaume Larid, Guy Baudens, Alexis Dandurand, Pascal Coquerelle, Vincent Goeb, Marie Helene Guyot, Laurent Marguerie, Frederic Maury, Eric Veillard, Eric Houvenagel, Jean-Hugues Salmon, Rene-Marc Flipo, Elisabeth Gervais
Summary: This study compared the treatment retention of subcutaneous boDMARDs and bsDMARDs in different diseases, molecules, and lines of treatment. The results showed that bsDMARDs had significantly better retention than boDMARDs, especially for ETN and patients with RA. Citrated treatments demonstrated better retention.
FRONTIERS IN MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Summary: FDA-approved anti-TNF alpha biopharmaceuticals have been successful in treating autoimmune diseases, but there are product-specific differences in patient outcomes, possibly due to structural and functional differences. In this study, we compared the structural and functional differences among three anti-TNF alpha mAbs (Humira (R), Remicade (R), and Simponi Aria (R)) to understand their implications on efficacy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Medicine, General & Internal
Yusuke Yoshimura, Shun Watanabe, Masayuki Yamanouchi, Daisuke Ikuma, Hiroki Mizuno, Akinari Sekine, Eiko Hasegawa, Tatsuya Suwabe, Kei Kono, Keiichi Kinowaki, Kenichi Ohashi, Yoshifumi Ubara, Naoki Sawa
Summary: We encountered an 86-year-old Japanese woman with proteinuria, hematuria, decreased renal function, and elevated MPO-ANCA levels during treatment of rheumatoid arthritis. Kidney biopsy showed pauci-immune necrotizing glomerulonephritis and ANCA-associated vasculitis was diagnosed. Treatment with tocilizumab resulted in improvement of renal findings and normalization of disease activity and serum ANCA levels.
Article
Gastroenterology & Hepatology
Nicholas A. Kennedy, James R. Goodhand, Claire Bewshea, Rachel Nice, Desmond Chee, Simeng Lin, Neil Chanchlani, Jeffrey Butterworth, Rachel Cooney, Nicholas M. Croft, Ailsa L. Hart, Peter M. Irving, Klaartje B. Kok, Christopher A. Lamb, Jimmy K. Limdi, Jonathan Macdonald, Dermot Pb McGovern, Shameer J. Mehta, Charles D. Murray, Kamal Patel, Richard C. G. Pollok, Timothy Raine, Richard K. Russell, Christian P. Selinger, Philip J. Smith, Jack Bowden, Timothy J. McDonald, Charlie W. Lees, Shaji Sebastian, Nicholas Powell, Tariq Ahmad
Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.
Review
Cardiac & Cardiovascular Systems
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Armando Puocci, Antonella De Angelis, Liberata Sportiello, Raffaele Marfella, Michelangela Barbieri
Summary: Atherosclerosis is an inflammatory disease that leads to cardiovascular mortality and morbidity. Type 2 diabetes mellitus is a known risk factor for atherosclerosis. Sodium-glucose co-transporter 2 inhibitors have been found to have anti-inflammatory effects and can potentially slow down the progression of atherosclerosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Cardiac & Cardiovascular Systems
Andrea Giachi, Massimo Cugno, Roberta Gualtierotti
Summary: Rheumatoid arthritis is not only related to joint issues, but also to cardiovascular disease. Chronic inflammation plays a key role in accelerating atherosclerosis. Disease-modifying anti-rheumatic drugs can improve cardiovascular risk.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Immunology
Fabien Francois, Loubna Naimi, Xavier Roblin, Anne-Emmanuelle Berger, Stephane Paul
Summary: The study evaluated the LISA-TRACKER assays for monitoring ABP501 and anti-ABP501 antibodies in human serum, showing that the assays are reliable and accurate. The results demonstrated the validity and consistency of using LISA-TRACKER for monitoring patients treated with ABP501.
Article
Biochemistry & Molecular Biology
Eu Jeong Ku, Bo-Rahm Kim, Jee-In Lee, Yun Kyung Lee, Tae Jung Oh, Hak C. Jang, Sung Hee Choi
Summary: Anakinra, a recombinant human IL-1 receptor antagonist, has been found to have inhibitory effects on the progression of atherosclerosis. It reduces plaque size and serum triglyceride levels, and suppresses inflammatory gene expressions and cell migration. In animal experiments, it also decreases macrophage infiltration and monocyte chemoattractant protein-1 expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Hironao Okubo, Tsuneo Kitamura, Hitoshi Ando, Hiroo Fukada, Yuki Igusa, Shigehiro Kokubu, Akihisa Miyazaki, Akio Fujimura, Shuichiro Shiina, Sumio Watanabe
JOURNAL OF CLINICAL PHARMACOLOGY
(2017)
Article
Oncology
Ken Shimada, Kentaro Ushijima, Chisato Suzuki, Michiko Horiguchi, Hitoshi Ando, Tomomi Akita, Mizuki Shimamura, Junki Fujii, Chikamasa Yamashita, Akio Fujimura
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2018)
Article
Multidisciplinary Sciences
Hironao Okubo, Hitoshi Ando, Yushi Sorin, Eisuke Nakadera, Hiroo Fukada, Junichi Morishige, Akihisa Miyazaki, Kenichi Ikejima
Article
Multidisciplinary Sciences
Ryo Miyazaki, Hitoshi Ando, Tomoko Hamasaki, Yukito Higuchi, Kazushige Oshita, Tomoki Tashiro, Naoki Sakane
Article
Nutrition & Dietetics
Tomoko Fujiwara, Masanori Ono, Michihiro Mieda, Hiroaki Yoshikawa, Rieko Nakata, Takiko Daikoku, Naomi Sekizuka-Kagami, Yoshiko Maida, Hitoshi Ando, Hiroshi Fujiwara
Article
Nutrition & Dietetics
Hironao Okubo, Hitoshi Ando, Eisuke Nakadera, Kenichi Ikejima, Shuichiro Shiina, Akihito Nagahara
Summary: The study demonstrated that levocarnitine supplementation can effectively suppress the progression of sarcopenia in patients with hepatocellular carcinoma receiving lenvatinib therapy, and is significantly correlated with free carnitine levels.
Review
Biochemistry & Molecular Biology
Masanori Ono, Hitoshi Ando, Takiko Daikoku, Tomoko Fujiwara, Michihiro Mieda, Yasunari Mizumoto, Takashi Iizuka, Kyosuke Kagami, Takashi Hosono, Satoshi Nomura, Natsumi Toyoda, Naomi Sekizuka-Kagami, Yoshiko Maida, Naoaki Kuji, Hirotaka Nishi, Hiroshi Fujiwara
Summary: The circadian rhythm, controlled by clock genes, is crucial for reproduction. In the mouse uterus, the oscillation of circadian clock gene has been observed. CLOCK-BMAL1 heterodimer promotes the transcription of Per1/2 and Cry1/2 genes by binding to their promoters' E-box sequences. The endometrial clock plays an important role in pregnancy, and disruptions in the uterine clock can lead to complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Medicinal
Hironao Okubo, Hitoshi Ando, Yusuke Takasaki, Eisuke Nakadera, Yuka Fukuo, Shuichiro Shiina, Kenichi Ikejima
Summary: This study investigated the impact of cabozantinib exposure on proteinuria and muscle toxicity in Japanese patients with unresectable hepatocellular carcinoma. The findings suggest that cabozantinib treatment can lead to proteinuria and muscle toxicity, which can be predicted by measuring serum creatine kinase and aldolase levels.
Review
Medicine, General & Internal
Naoto Nagata, Guanliang Chen, Liang Xu, Hitoshi Ando
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease, and hepatic inflammation plays a crucial role in its development. Chemokines, especially CCL2 and CCL5, are important in inducing insulin resistance, steatosis, inflammation, and fibrosis in NAFLD. Cenicriviroc (CVC), a dual antagonist of chemokine receptors, has shown potential as a therapeutic approach for NASH-associated liver fibrosis.
MEDICINA-LITHUANIA
(2022)
Article
Medicine, General & Internal
Nazmul Hasan, Koki Sugimoto, Koki Yamada, Jun-ichi Morishige, Kentaro Ushijima, Akio Fujimura, Naoto Nagata, Hitoshi Ando
Summary: This study investigated whether chronic treatment with the antidiabetic agent metformin impairs circadian clocks, especially if given at an inappropriate time. The results showed that chronic treatment with metformin does not disrupt circadian clock gene expression in peripheral tissues and affects hepatic AMPK activation rhythm in diabetic mice.
MEDICINA-LITHUANIA
(2022)
Article
Biology
Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
CHRONOBIOLOGY INTERNATIONAL
(2018)
Meeting Abstract
Gastroenterology & Hepatology
Hironao Okubo, Hitoshi Ando, Yushi Sorin, Eisuke Nakadera, Hiroo Fukada, Yuki Igusa, Akihisa Miyazaki, Kenichi Ikejima
Article
Pharmacology & Pharmacy
Kentaro Ushijima, Hitoshi Ando, Yusuke Arakawa, Kenichi Aizawa, Chisato Suzuki, Ken Shimada, Shu-ichi Tsuruoka, Akio Fujimura
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2017)
Meeting Abstract
Pharmacology & Pharmacy
Hitoshi Ando
JOURNAL OF PHARMACOLOGICAL SCIENCES
(2017)